Effect of St John's wort on imatinib mesylate pharmacokinetics

Clinical Pharmacology and Therapeutics

Volumn 76, Issue 4, 2004, Pages 323-329

  Frye, Reginald F ^a,c   Fitzgerald, Sara M ^a   Lagattuta, Theodore F ^b   Hruska, Matthew W ^c   Egorin, Merrill J ^b,d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CGP 74588; DRUG METABOLITE; HYPERICUM PERFORATUM EXTRACT; IMATINIB; KIRA; N NORIMATINIB; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENTIATION; FEMALE; HUMAN; HYPERICUM PERFORATUM; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADULT; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; HYPERICUM; MALE; MIDDLE AGED; PHYTOTHERAPY; PIPERAZINES; PLANT EXTRACTS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 4744338886     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.06.007     Document Type: Article

References (30)

1. P. Traxler, G. Bold, E. Buchdunger, G. Caravatti, P. Furet, P Manley Tyrosine kinase inhibitors: from rational design to clinical trials Med Res Rev 21 2001 499 512
2. E. Buchdunger, J. Zimmermann, H. Mett, T. Meyer, M. Muller, B.J Druker Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res 56 1996 100 104
3. B.J. Druker, C.L. Sawyers, H. Kantarjian, D.J. Resta, S.F. Reese, J.M Ford Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 2001 1038 1042
4. B.J. Druker, M. Talpaz, D.J. Resta, B. Peng, E. Buchdunger, J.M Ford Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037
5. G.D. Demetri, M. von Mehren, C.D. Blanke, A.D. Van den Abbeele, B. Eisenberg, P.J Roberts Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 2002 472 480
6. Gleevec (imatinib mesylate) 2002 Novartis Pharmaceuticals East Hanover (NJ) [full prescribing information]
7. Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, Pokorny R, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004;54:290-4.
8. A.E. Bolton, B. Peng, M. Hubert, A. Krebs-Brown, R. Capdeville, U Keller Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects Cancer Chemother Pharmacol 53 2004 102 106
9. S.C. Piscitelli, A.H. Burstein, D. Chaitt, R.M. Alfaro, J. Falloon Indinavir concentrations and St John's wort Lancet 355 2000 547 548
10. M.F. Hebert, J.M. Park, Y.L. Chen, S. Akhtar, A.M. Larson Effects of St John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers J Clin Pharmacol 44 2004 89 94
11. S.D. Hall, Z. Wang, S.M. Huang, M.A. Hamman, N. Vasavada, A.Q Adigun The interaction between St John's wort and an oral contraceptive Clin Pharmacol Ther 74 2003 525 535
12. X. Jiang, K.M. Williams, W.S. Liauw, A.J. Ammit, B.D. Roufogalis, C.C Duke Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects Br J Clin Pharmacol 57 2004 592 599
13. L.B. Moore, B. Goodwin, S.A. Jones, G.B. Wisely, C.J. Serabjit-Singh, T.M Willson St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor Proc Natl Acad Sci U S A 97 2000 7500 7502
14. M.A. Richardson, T. Sanders, J.L. Palmer, A. Greisinger, S.E. Singletary Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology J Clin Oncol 18 2000 2505 2514
15. N. Aass, S.D. Fossa, A.A. Dahl, T.J. Moe Prevalence of anxiety and depression in cancer patients seen at the Norwegian Radium Hospital Eur J Cancer 33 1997 1597 1604
16. R.A. Parise, R.K. Ramanathan, M.J. Hayes, M.J. Egorin Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma J Chromatogr B Analyt Technol Biomed Life Sci 791 2003 39 44
17. M. Ohno, I. Yamaguchi, K. Saiki, I. Yamamoto, J. Azuma Specific determination of urinary 6beta-hydroxycortisol and cortisol by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry J Chromatogr B Biomed Sci Appl 746 2000 95 9101
18. C. Tang, K. Kassahun, I.S. McIntosh, J. Brunner, A.D. Rodrigues Simultaneous determination of urinary free cortisol and 6beta-hydroxycortisol by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry and its application for estimating hepatic CYP3A induction J Chromatogr B Biomed Sci Appl 742 2000 303 313
19. S.J. Kovacs, D.E. Martin, D.E. Everitt, S.D. Patterson, D.K. Jorkasky Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations Clin Pharmacol Ther 63 1998 617 622
20. P. le Coutre, K.A. Kreuzer, S. Pursche, M. Bonin, T. Leopold, G Baskaynak Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588 Cancer Chemother Pharmacol 53 2004 313 323
21. C.A. Roby, G.D. Anderson, E. Kantor, D.A. Dryer, A.H. Burstein St John's wort: effect on CYP3A4 activity Clin Pharmacol Ther 67 2000 451 457
22. S. Bauer, E. Stormer, R. Kerb, A. Johne, J. Brockmoller, I. Roots Differential effects of Saint John's wort (Hypericum perforatum) on the urinary excretion of D-glucaric acid and 6beta-hydroxycortisol in healthy volunteers Eur J Clin Pharmacol 58 2002 581 585
23. M. Wenk, L. Todesco, S. Krahenbuhl Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females Br J Clin Pharmacol 57 2004 495 499
24. P. Damkier, L.L. Hansen, K. Brosen Rifampicin treatment greatly increases the apparent oral clearance of quinidine Pharmacol Toxicol 85 1999 257 262
25. S. Saima, K. Furuie, H. Yoshimoto, J. Fukuda, T. Hayashi, H. Echizen The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects Br J Clin Pharmacol 53 2002 203 206
26. J.Q. Tran, S.J. Kovacs, T.S. McIntosh, H.M. Davis, D.E. Martin Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction J Clin Pharmacol 39 1999 487 494
27. B. Peng, C. Dutreix, G. Mehring, M.J. Hayes, M. Ben-Am, M Seiberling Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion J Clin Pharmacol 44 2004 158 162
28. Z. Wang, J.C. Gorski, M.A. Hamman, S.M. Huang, L.J. Lesko, S.D. Hall The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity Clin Pharmacol Ther 70 2001 317 326
29. B. Peng, M. Hayes, D. Resta, A. Racine-Poon, B.J. Druker, M Talpaz Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients J Clin Oncol 22 2004 935 942
30. H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, F Giles High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia Blood 103 2004 2873 2878